Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Minetta C Liu

Showing results (71-80 of 159) with videos related to

Pageof 16
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Plos One|June 10, 2021
Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancerTommaso Grassi, Faye R Harris, James B Smadbeck, et al.
Molecular Oncology|December 1, 2023
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumorsEkaterina Kalashnikova, Vasily N Aushev, Allyson Koyen Malashevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast CancerSiang-Boon Koh, Kenneth Ross, Steven J Isakoff, et al.
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2025
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece TrialsJulien Taieb, John Souglakos, Ioannis Boukovinas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2023
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung CancerBruna Pellini, Russell W Madison, Merrida A Childress, et al.
Cancer Treatment Reviews|February 1, 2008
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxelMinetta C Liu, George D Demetri, Donald A Berry, et al.
European Urology Oncology|June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± PembrolizumabKevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Journal for Immunotherapy of Cancer|September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapyHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Pageof 16

Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 22, 2015
Use of Biomarkers to Guide Decisions on Systemic Therapy for Women With Metastatic Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineCatherine Van Poznak, Mark R Somerfield, Robert C Bast, et al.
Plos One|June 10, 2021
Personalized tumor-specific DNA junctions to detect circulating tumor in patients with endometrial cancerTommaso Grassi, Faye R Harris, James B Smadbeck, et al.
Molecular Oncology|December 1, 2023
Correlation between variant allele frequency and mean tumor molecules with tumor burden in patients with solid tumorsEkaterina Kalashnikova, Vasily N Aushev, Allyson Koyen Malashevich, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
RASAL2 Confers Collateral MEK/EGFR Dependency in Chemoresistant Triple-Negative Breast CancerSiang-Boon Koh, Kenneth Ross, Steven J Isakoff, et al.
Breast Cancer Research : BCR|February 20, 2020
TBCRC 002: a phase II, randomized, open-label trial of preoperative letrozole with or without bevacizumab in postmenopausal women with newly diagnosed stage 2/3 hormone receptor-positive and HER2-negative breast cancerChristos Vaklavas, Brian S Roberts, Katherine E Varley, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 4, 2025
Combined Analyses of Circulating Tumor DNA and Immunoscore in Patients With Stage III Colon Cancer: A Post Hoc Analysis of the PRODIGE-GERCOR IDEA-France/HORG-IDEA-Greece TrialsJulien Taieb, John Souglakos, Ioannis Boukovinas, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 13, 2023
Circulating Tumor DNA Monitoring on Chemo-immunotherapy for Risk Stratification in Advanced Non-Small Cell Lung CancerBruna Pellini, Russell W Madison, Merrida A Childress, et al.
Cancer Treatment Reviews|February 1, 2008
Dose-escalation of filgrastim does not improve efficacy: clinical tolerability and long-term follow-up on CALGB study 9141 adjuvant chemotherapy for node-positive breast cancer patients using dose-intensified doxorubicin plus cyclophosphamide followed by paclitaxelMinetta C Liu, George D Demetri, Donald A Berry, et al.
European Urology Oncology|June 30, 2026
Prognostic Implications of Personalized Circulating Tumor DNA Testing in Patients with Advanced Urothelial Carcinoma Treated with Enfortumab Vedotin ± PembrolizumabKevin R Reyes, Ryan Zhu, Cameron Herberts, et al.
Journal for Immunotherapy of Cancer|September 22, 2025
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapyHillary S Andrews, Nevine Zariffa, Katherine K Nishimura, et al.
Pageof 16